A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue
- PMID: 30360032
- PMCID: PMC6351792
- DOI: 10.4082/kjfm.17.0064
A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue
Abstract
Background: This double-blind, randomized controlled design study aimed to assess the dose-dependent effects of synbiotics on gastrointestinal symptoms of and fatigue in irritable bowel syndrome (IBS).
Methods: Thirty subjects with IBS were randomly assigned into the following three groups and received 2 capsules a day for 8 weeks: (1) high-dose (2 capsules of synbiotics); (2) low-dose (1 capsule of synbiotics and 1 capsule of placebo); and (3) placebo (2 capsules of placebo). At baseline and 8 weeks, they completed the study questionnaires.
Results: Two subjects in the high-dose group were lost to follow-up, leaving a total of 28 patients for the analysis. After 8 weeks, abdominal discomfort, abdominal bloating, frequency of formed stool, fatigue Visual Analog Scale (VAS), and Multidimensional Fatigue Inventory were significantly different among the groups (P=0.002, 0.006, 0.007, 0.028, and 0.041, respectively, by Kruskal-Wallis test). However, only abdominal discomfort, abdominal bloating, frequency of formed stool, and fatigue VAS were significantly improved in the high-dose group compared with those in the placebo group (P=0.002, 0.003, 0.002, and 0.013, respectively) by Mann-Whitney test with Bonferroni correction. No adverse drug reactions were reported.
Conclusion: High-dose synbiotics were superior to placebo in improving bowel symptoms and fatigue of IBS patients, suggesting that synbiotic dosage plays an important role in the treatment of IBS.
Keywords: Dose-Response Relationship; Fatigue; Irritable Bowel Syndrome; Probiotics; Synbiotics.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.Gut Liver. 2023 Jan 15;17(1):100-107. doi: 10.5009/gnl210478. Epub 2022 May 25. Gut Liver. 2023. PMID: 35611667 Free PMC article. Clinical Trial.
-
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685. doi: 10.1016/S2468-1253(19)30198-0. Epub 2019 Jul 17. Lancet Gastroenterol Hepatol. 2019. PMID: 31326345 Clinical Trial.
-
Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial.Turk J Gastroenterol. 2016 Sep;27(5):439-443. doi: 10.5152/tjg.2016.16301. Turk J Gastroenterol. 2016. PMID: 27782892 Clinical Trial.
-
Symbiotics in irritable bowel syndrome--better than probiotics alone?Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):485-9. doi: 10.1097/MCO.0000000000000199. Curr Opin Clin Nutr Metab Care. 2015. PMID: 26107141 Review.
-
Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome.Curr Med Res Opin. 2014 Jul;30(7):1405-15. doi: 10.1185/03007995.2014.908278. Epub 2014 Apr 14. Curr Med Res Opin. 2014. PMID: 24666019 Review.
Cited by
-
How to Improve Health with Biological Agents-Narrative Review.Nutrients. 2022 Apr 20;14(9):1700. doi: 10.3390/nu14091700. Nutrients. 2022. PMID: 35565671 Free PMC article. Review.
-
Synbiotics as Treatment for Irritable Bowel Syndrome: A Review.Microorganisms. 2024 Jul 21;12(7):1493. doi: 10.3390/microorganisms12071493. Microorganisms. 2024. PMID: 39065261 Free PMC article. Review.
-
Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review.Biomolecules. 2021 Aug 4;11(8):1154. doi: 10.3390/biom11081154. Biomolecules. 2021. PMID: 34439821 Free PMC article. Review.
-
Antioxidant and anti-inflammatory properties of water kefir microbiota and its bioactive metabolites for health promoting bio-functional products and applications.AIMS Microbiol. 2024 Sep 5;10(4):756-811. doi: 10.3934/microbiol.2024034. eCollection 2024. AIMS Microbiol. 2024. PMID: 39628717 Free PMC article. Review.
-
Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome.Gastroenterol Res Pract. 2019 Dec 1;2019:9759138. doi: 10.1155/2019/9759138. eCollection 2019. Gastroenterol Res Pract. 2019. PMID: 31885549 Free PMC article. Review.
References
-
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–91. - PubMed
-
- Han SH, Lee OY, Bae SC, Lee SH, Chang YK, Yang SY, et al. Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. J Gastroenterol Hepatol. 2006;21:1687–92. - PubMed
-
- Spiegel BM. Burden of illness in irritable bowel syndrome: looking beyond the patient. Clin Gastroenterol Hepatol. 2013;11:156–7. - PubMed
-
- Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol. 2008;103:1557–67. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources